Comparative Pharmacology
Head-to-head clinical analysis: ELFABRIO versus NAGLAZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELFABRIO versus NAGLAZYME.
ELFABRIO vs NAGLAZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
NAGLAZYME (galsulfase) is a recombinant form of human N-acetylgalactosamine 4-sulfatase that replaces deficient endogenous enzyme in patients with mucopolysaccharidosis VI (MPS VI). It catalyzes the hydrolysis of N-acetylgalactosamine 4-sulfate groups from glycosaminoglycans (GAGs), reducing GAG accumulation in lysosomes.
1 mg/kg intravenously over 2 hours every 2 weeks.
1 mg/kg intravenously once weekly.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Terminal elimination half-life: 6-9 minutes (0.1-0.15 hours); clinically, rapid clearance requires weekly intravenous administration to maintain therapeutic levels.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Renal: 87% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy